Recall: Quinapril-Hctz
Nov. 2022Pharmacy Updates
Aurobindo Pharma USA Inc. has recalled two lots of quinapril and hydrochlorothiazide tablets due to detection of a nitrosamine (N-nitrosoquinapril) impurity in amounts above the Acceptable Daily Intake level. Nitrosamines may increase the risk of cancer if people are exposed to them above acceptable levels over long periods of time. Read the full text of the Quinapril-Hctz recall.
Recent Announcements
The importance of PRD forms for complex patients and staying updated on changes
Personal representative designation (PRD) forms are critical to the care process for patients and providers alike. Not only do PRDs support accurate, efficient, and compliant patient care—they also streamline administrative processes.Aug. 2025Important Notices
Important announcement: UPMC Health Plan retires MP.PA.147
This communication is in regards to UPMC Health Plan Policy MP.PA.147 – Diagnostic and Surveillance Colonoscopy, 18 Years Old and Older. UPMC Health Plan previously communicated that the prior authorization requirement under this policy would be paused until Sept. 1, 2025. However, policy MP.PA.147 has been retired, and this policy will no longer be implemented or active.Aug. 2025Important Notices
CMS expands Medicare Advantage RADV audits to all eligible plans
On May 21, 2025, the Centers for Medicare & Medicaid Services (CMS) announced a substantial expansion of its Risk Adjustment Data Validation (RADV) audit program for Medicare Advantage plans.Aug. 2025What's New